SYS-CON MEDIA Authors: Elizabeth White, Pat Romanski, Doug Masi, Mat Mathews, PR.com Newswire

News Feed Item

Halozyme to Host second Quarter 2014 Financial Results Conference Call

SAN DIEGO, Aug. 4, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2014 on Monday, August 11, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the second quarter 2014.

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (866) 710-0179 (domestic callers) or (334) 323-7224 (international callers) using passcode 769890. A telephone replay will be available shortly after the call by dialing (877) 919-4059 (domestic callers) or (334) 323-0140 (international callers) using replay ID number 71625396.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including oncology, diabetes, and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, and Baxter. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
[email protected]

Media Contact:
Susan Neath Francis
212-301-7182
[email protected]

Halozyme Therapeutics, Inc. Logo

Logo - http://photos.prnewswire.com/prnh/20100302/LA63139LOGO

SOURCE Halozyme Therapeutics, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.